The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients. We have more ideas, we see more opportunities and we want to transform the horizon of therapeutic options. In order to achieve this, we will develop Idorsia into one of Europe’s leading biopharmaceutical companies, with a strong scientific core.
Idorsia - Key investment highlights
Strategy
Advance late-stage pipeline.
Successfully launch our new products.
Bring Idorsia to sustainable profitability.
Fuel our pipeline with new discoveries.
Utilize state-of-the-art technologies to drive innovation.
Pipeline
Diversified mostly unencumbered clinical development pipeline.
Late-stage compounds with the potential to transform the target indication treatment landscape.
Broad early-stage pipeline of promising drugs in development.
Colllaboration with credible partners.
People
Entrepreneurial mangement and organization led by Actelion founders.
Proven track record of successfully bringing drug candidates to market.
R&D organization with highly qualified specialists.
Significant equity stake of Clozel family.
Strategic priorities
Find out more about the key priorities that management has set in order to develop Idorsia into one of Europe’s leading biopharmaceutical companies.
Our Portfolio
We have a diversified and balanced portfolio covering multiple therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.
For investors, we provide more information on how Idorsia is innovating to change treatment paradigms in our innovation fact sheet.
